Androgens and NAFLD_Suzuki (Nonalcoholic Fatty Liver Disease) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about how androgens, a type of sex hormone, might affect women who have nonalcoholic fatty liver disease (NAFLD). We want to see if they play a role in how the disease effects women over time, and we also want to see what role these hormones might play in the relationship between NAFLD and polycystic ovary syndrome.
What is the Condition Being Studied?
Nonalcoholic Fatty Liver Disease (NAFLD)
Who Can Participate in the Study?
Women ages 18-42 who:
- Are diagnosed with or suspected to have metabolic associated steatohepatitis (MASH) as defined by previous liver biopsy or fibroscan results
- Have or do not have polycystic ovary syndrome
- Do not have intestinal dysfunction, HIV, diabetes, or cancer
- Have not had weight loss surgery or significant weight loss in the past 3 months
- Do not use anabolic steroids or any type of anti-androgen medication
For more information, contact the study team at angela.braswell@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Consult with a hepatologist (doctor who specializes in the liver) about lifestyle factors like physical activity, nutrition, substance use, and medical history
- Have a fibroscan (an ultrasound based imaging scan that measures scarring in the liver)
- Have physical exams
- Have a liver MRI to measure the amount of fat around the liver
- Have blood draws
Study Details
Full Title
Androgens and Nonalcoholic Fatty Liver Disease (NAFLD) in Reproductive-Aged Women With and Without Polycystic Ovary Syndrome (PCOS)
Principal Investigator
Ayako Suzuki
Protocol Number
IRB:
PRO00113782
Phase
Phase
N/A
Enrollment Status
Open for Enrollment